RAET1L

Across TCGA pan-cancer cohorts, RAET1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAET1L data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RAET1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAET1L expression acts as an unfavorable survival marker.

LUSC, UCEC, and LUAD are the cancer types where RAET1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	36	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.545	0.812	.008	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAET1L–LUSC (DFS)

Open the LUSC breakdown →